A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-07 and is reviewed periodically as new material appears.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Those peptides expressing a drug-related, non-self epitope on one of their various HLA protein forms (HLA-A, HLA-B, HLA-C, HLA-DM, HLA-DO, HLA-DP, HLA-DQ, or HLA-DR) can bind to a T-cell receptor and thereby stimulate the receptor-bearing parent T cell to initiate attacks on self tissues. Alternatively, a drug or its metabolite may stimulate these T cells by inserting into the groove on a HLA protein to serve as a non-self epitope or bind outside of this groove to alter a HLA protein so that it forms a non-self epitope. In all these cases, however, a non-self epitope must bind to a specific HLA serotype (i.e. variation) in order to stimulate T cells. Since the human population expresses some 13,000 different HLA serotypes while an individual expresses only a fraction of them and since a SJS-inducing drug or metabolite interacts with only one or a few HLA serotypes, a drug's ability to induce SCARs is limited to those individuals who express HLA serotypes targeted by the drug or its metabolite. Accordingly, only rare individuals are predisposed to develop a SCARs in response to a particular drug on the bases of their expression of HLA serotypes: Studies have identified several HLA serotypes associated with development of SJS, SJS/TEN, or TEN in response to certain drugs. In general, these associations are restricted to the cited populations. In some East Asian populations studied (Han Chinese and Thai), carbamazepine- and phenytoin-induced SJS is strongly associated with HLA-B*1502 (HLA-B75), an HLA-B serotype of the broader serotype HLA-B15.
==== Warp Drive Bio ==== In 2012, Verdine founded Warp Drive Bio with cofounders George Church and James Wells. The company maps the genomes of soil-dwelling microbes in the search for potential treatments for drug-resistant ailments. In 2013, Verdine became full-time CEO of Warp Drive Bio, then handed the CEO position to Lawrence Reid in 2016 in order to found two new startups, FogPharma and LifeMine.
Bordered by Corso Castelfidardo, Corso Vittorio Emanuele II, Corso Trapani and Corso Peschiera, this small district is mainly significant for hosting the recent expansion of Turinese institute of technology Politecnico. The expansion was possible after under-grounding the railway under Corso Castelfidardo and the subsequent disposal of the old buildings dedicated to the train maintenance present in this area (so-called Officine Grandi Riparazioni or OGR). Politecnico expanded its facilities through two huge overpass buildings over the avenue, linked to new buildings on the west side. This cluster of buildings forms an evocative square with a unique architectural style. The main building on the west side hosts a General Motors research centre, the General Motors Global Propulsion Systems (formerly known as General Motors Powertrain Europe). Politecnico area extends until Via Boggio with further facilities hosted in the former OGR facilities. The institute plans to further build new facilities in the current parking area. North of Politecnico facilities, the main building of the OGR former cluster, became an open space which hosts temporary exhibitions. During the hot seasons, its external spaces became a fashionable site to have a typical Italian aperitivo. North of OGR, a former prison complex called Le Nuove is a significant example of old European prison building. The complex was built between 1857 and 1869 during the reign of Victor Emmanuel II. After being disposed of during the 1990s, the complex was changed into a museum and it is possible to visit its facilities.
Russian President Vladimir Putin acknowledged that the "special military operation" was taking longer than expected but claimed the country's nuclear arsenal was preventing the conflict from escalating. As in June 2022, he made another reference to the expansion of the Russian Empire by Peter the Great. The Ukrainian General Staff claimed to have launched multiple strikes against Russian logistic lines near the cities of Berdyansk, Tokmak, Melitopol, Enerhodar, Dniprorudne, Polohy, and Vasylivka, Zaporizhia Oblast. They claimed 240 Russians were wounded and 20 pieces of military equipment were destroyed in the strikes.
Sources: en.wikipedia.org
=== Early life, start of career and Basel === Photaki was born in Corinth in 1921 and finished her secondary education at the 2nd Girls' Gymnasium of Athens in 1938. In the same year she enrolled at the Department of Chemistry in the University of Athens, where she specialised in Organic chemistry under the mentorship of Leonidas Zervas. Her studies were interrupted during the Axis occupation of Greece when the Laboratory of Organic Chemistry was destroyed and Zervas was imprisoned as a member of the Greek Resistance. Photaki was finally awarded her degree summa cum laude in 1946 and subsequently continued her postgraduate studies under Zervas, earning her PhD in 1950 with a dissertation regarding glucosamine. Concurrently, she held a paid laboratory assistant position at the university already from 1943, carrying on as a research assistant until 1953. In 1953, Photaki was awarded a scholarship to conduct research in Basel after examinations by the Greek State Scholarships Foundation. At the University of Basel she worked in the Laboratory of Organic Chemistry, at the time headed by Nobel laureate Tadeusz Reichstein. For the first two years of her stay (1953–1955) she was part of the Max Brenner research group, later moving as an independent scientific associate of Hans Erlenmeyer. Upon returning to Greece, she initially worked at the biochemical lab of the Evangelismos Hospital before being invited by Zervas to the nascent National Hellenic Research Foundation (NHRF) which he had helped found.
=== Generic names === Opipramol is the English, German, French, and Spanish generic name of the drug and its INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française, while opipramol hydrochloride is its USANTooltip United States Adopted Name, BANMTooltip British Approved Name, and JANTooltip Japanese Accepted Name. Its generic name in Italian and its DCITTooltip Denominazione Comune Italiana is opipramolo and in Latin is opipramolum.
Peukert argued that despite a turn towards Social Darwinism when confronted with the failure of the welfare state to solve all social problems in the 1920s, that it was the democratic Weimar constitution that had provided a thin legal wedge that prevented the full implications of this from being worked out. Peukert argued that in 1939 that the entire system that had been built up for scientifically identifying those of racial "non-value" served as the apparatus for genocide. Peukert wrote that all of the criteria for identifying Jews and Romany as peoples of racial "non-value" were based on the pseudo-scientific theories that had been promoted by generations of "race scientists" and that those serving in the "human sciences and social professions" worked to provide the theories for an "all-embracing racist restructuring of social policy, educational policy and health and welfare policy". The culmination of these efforts was the proposed 1944 "Law for the Treatment of Community Aliens" which called for sending to the concentration camps anyone who failed to live be up to be a proper 'volksgenossen as a gemeinschaftsfremde (community alien). Only the fact that Germany was fully engaged in World War II prevented Hitler from signing "Law for the Treatment of Community Aliens", which was put off until the Reich won the "final victory". Peukert wrote: "Nazi racism, the professed goal which had been to secure the immortality of the racially pure volkskörper in practice inevitably became converted into a crusade against life".
Sources: en.wikipedia.org
In October 2023, the EMBARK trial showed improved metastasis-free survival in high-risk, non-metastatic prostate cancer patients, leading to the FDA approval of a combination therapy in 2023. In December 2023, the company acquired Seagen, a pioneer of antibody–drug conjugates for the treatment of cancer, for $43 billion. In December 2023, the EV-302 study investigated new treatments for advanced urothelial cancer, focusing on improving care for hard-to-treat patient groups. In January 2024, omnichannel strategies were being used to provide tailored healthcare solutions for patients and professionals. In February 2024, Saama and Pfizer reached an expanded multi-year agreement to integrate AI-driven solutions across Pfizer's R&D portfolio, building on their 2020 partnership. Initially the partnership focused on automating data review processes with the Smart Data Quality (SDQ) platform — developed during Pfizer's COVID-19 vaccine trials — the partnership as of 2024 scales to streamline data review and accelerate regulatory submissions across global studies. The expanded collaboration introduces Saama's Biometrics Research and Analysis Information Network, enabling faster statistical programming, biostatistics workflows, and submission-ready outputs. In February 2024, Pfizer reported durable second-season efficacy for RSV vaccine. In June 2024, Pfizer announced a collaboration with the Abu Dhabi Department of Health to analyze real-world data on Sickle Cell Disease using AI.
== Signs and symptoms == The signs and symptoms of an infection depend on the type of disease. Some signs of infection affect the whole body generally, such as fatigue, loss of appetite, weight loss, fevers, night sweats, chills, aches and pains. Others are specific to individual body parts, such as skin rashes, coughing, or a runny nose. In certain cases, infectious diseases may be asymptomatic for much or even all of their course in a given host. In the latter case, the disease may only be defined as a "disease" (which by definition means an illness) in hosts who secondarily become ill after contact with an asymptomatic carrier. An infection is not synonymous with an infectious disease, as some infections do not cause illness in a host.
== Ethnic/cultural affinity groups == Afro-American Association American Australian Association, a privately-funded nonprofit organization based in New York Amhara Association of America Australian American Association, a community organization based in Australia
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.